Neuronal mechanisms and the treatment of motion sickness

Pharmacology

Volumn 91, Issue 3-4, 2013, Pages 229-241

  Schmal F ^a  

^a Department of Otorhinolaryngology Head and Neck Surgery HNO Zentrum Münsterland   (Germany)

Author keywords

Drug treatment; Mechanisms; Motion sickness; Prevention; Treatment

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIHISTAMINIC AGENT; BACLOFEN; CHLOROFORM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; DEXAMETHASONE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUNARIZINE; GINSENOSIDE; HISTAMINERGIC RECEPTOR AFFECTING AGENT; LOPERAMIDE; MAROPITANT; NEUROLEPTIC AGENT; PHENYTOIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 3 ANTAGONIST;

ADAPTATION; AUDITORY CANAL; BARANY TEST; CLINICAL FEATURE; DISEASE PREDISPOSITION; HUMAN; MENSTRUATION; MICROGRAVITY; MIGRAINE; MOTION SICKNESS; NAUSEA AND VOMITING; NEUROPATHOLOGY; OTOLITH; PREGNANCY; PRIORITY JOURNAL; PROPRIOCEPTION; PSEUDOMOTION SICKNESS; REVIEW; SEMICIRCULAR CANAL; SENSORY STIMULATION; SUSCEPTIBLE POPULATION; VESTIBULAR SYSTEM; VISUAL INFORMATION; VISUAL SYSTEM;

EID: 84876457407     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000350185     Document Type: Review

References (122)

1. Brandt T, Daroff RB. The multisensory physiological and pathological vertigo syndromes. Ann Neurol 1980; 7: 195-203
2. Oosterveld WJ. Motion sickness. J Travel Med 1995; 2: 182-185
3. Wilson WD. Travel sickness in cattle. Vet Rec 1997; 140: 76
4. Kennedy RS, Graybiel A, McDonough RC, Beckwith FD. Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. Acta Otolaryngol 1968; 66: 533-540
5. Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990; 68: 294-303
6. Reason JT. Motion sickness adaptation: a neural mismatch model. J R Soc Med 1978; 71: 819-829
7. Reason JT, Brand JJ. Motion Sickness. London, Academic Press, 1975
8. Schmal F, Stoll W. Kinetosen. HNO 2000; 48: 346-356
9. Parker DM A psychophysiological test for motion-sickness susceptibility. J Gen Psychol 1971; 85: 87-92
10. Money KE. Motion sickness. Physiol Rev 1970; 50: 1-39
11. Oman CM A heuristic mathematical model for the dynamics of sensory conflict and motion sickness. Acta Otolaryngol Suppl 1982; 392: 1-44
12. Pitman JR, Yolton RL. Etiology and treatment of motion sickness: a review. J Am Optom Assoc 1983; 54: 31-38
13. Helling K, Hausmann S, Clarke A, Scherer H. Experimentally induced motion sickness in fish: possible role of the otolith organs. Acta Otolaryngol 2003; 123: 488-492
14. Beier M, Anken RH, Rahmann H. Influence of hypergravity on fish inner ear otoliths II Incorporation of calcium and kinetotic behaviour. Adv Space Res 2002; 30: 727-731
15. Hilbig R, Anken RH, Bauerle A, Rahmann H. Susceptibility to motion sickness in fish: a parabolic aircraft flight study. J Gravit Physiol 2002; 9: 29-30
16. Diamond SG, Markham CH. Validating the hypothesis of otolith asymmetry as a cause of space motion sickness. Ann NY Acad Sci 1992; 656: 725-731
17. Nooij SA, Vanspauwen R, Bos JE, Wuyts FL A re-investigation of the role of utricular asymmetries in space motion sickness. J Vestib Res 2011; 21: 141-151
18. Takabayashi A, Ohmura-Iwasaki T. Functional asymmetry estimated by measurements of otolith in fish. Biol Sci Space 2003; 17: 293-297
19. Xie SJ, Chen W, Jia HB, Wang ZJ, Yao Q, Jiang YY. Ocular vestibular evoked myogenic potentials and motion sickness susceptibility. Aviat Space Environ Med 2012; 83: 14-18
20. Tal D, Hershkovitz D, Kaminski G, Bar R. Vestibular evoked myogenic potential threshold and seasickness susceptibility. J Vestib Res 2006; 16: 273-278
21. Liu L, Yuan L, Wang HB, Yu LS, Zheng J, Luo CQ, Wang Y. The human alpha(2A)-AR gene and the genotype of site -1296 and the susceptibility to motion sickness (in Chinese). Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002; 34: 291-297
22. Reavley CM, Golding JF, Cherkas LF, Spector TD, MacGregor AJ. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med 2006; 77: 1148-1152
23. Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006; 77: 1213-1223
24. Nashner LM, Peters JF. Dynamic posturography in the diagnosis and management of dizziness and balance disorders. Neurol Clin 1990; 8: 331-349
25. Scherer H, Frohlich G. Reactions to coriolis stimulations and postrotatory ENG-response A study on pilot-candidates and pilots. Acta Otolaryngol 1972; 74: 113-117
26. Scherer H, Helling K, Hausmann S, Clarke AH. On the origin of interindividual susceptibility to motion sickness. Acta Otolaryngol 1997; 117: 149-153
27. Klosterhalfen S, Kellermann S, Pan F, Stockhorst U, Hall G, Enck P. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med 2005; 76: 1051-1057
28. Jokerst MD, Gatto M, Fazio R, Gianaros PJ, Stern RM, Koch KL. Effects of gender of subjects and experimenter on susceptibility to motion sickness. Aviat Space Environ Med 1999; 70: 962-965
29. Grunfeld E, Gresty MA. Relationship between motion sickness, migraine and menstruation in crew members of a 'round the world' yacht race. Brain Res Bull 1998; 47: 433-436
30. Golding JF, Kadzere P, Gresty MA. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med 2005; 76: 970-973
31. Matchock RL, Levine ME, Gianaros PJ, Stern RM. Susceptibility to nausea and motion sickness as a function of the menstrual cycle. Womens Health Issues 2008; 18: 328-335
32. Cheung B, Heskin R, Hofer K, Gagnon M. The menstrual cycle and susceptibility to coriolis-induced sickness. J Vestib Res 2001; 11: 129-136
33. McIntosh IB. Motion sickness - questions and answers. J Travel Med 1998; 5: 89-91
34. Busoni P, Sarti A, Crescioli M, Agostino MR, Sestini G, Banti S. Motion sickness and postoperative vomiting in children. Paediatr Anaesth 2002; 12: 65-68
35. Dichgans J, Brandt T. Visual-vestibular interaction in self-motion perception and postural control; in Teuber L, Held R, Leibowitz HW (eds): Handbook of Sensory Physiology. Springer Verlag Berlin Heidelberg, 1976, vol 5
36. Fischer AJ, Oosterveld WJ. Motion sickness (author's transl). HNO 1979; 27: 285-291
37. Yardley L. Motion sickness susceptibility and the utilisation of visual and otolithic information for orientation. Eur Arch Otorhinolaryngol 1990; 247: 300-304
38. Wood R. The 'haunted swing' illusion. Psychol Rev 1895; 2: 277-278
39. Kubo T, Matsunaga T, Matano S. Correlation between vestibular nuclei and the hypothalamus in the rat. Int J Equilib Res 1974; 4: 28-36
40. Koch KL, Summy-Long J, Bingaman S, Sperry N, Stern RM. Vasopressin and oxytocin responses to illusory self-motion and nausea in man. J Clin Endocrinol Metab 1990; 71: 1269-1275
41. Takeda N, Morita M, Kubo T, Yamatodani A, Watanabe T, Wada H, Matsunaga T. Histaminergic mechanism of motion sickness. Neurochemical and neuropharmacological studies in rats. Acta Otolaryngol 1986; 101: 416-421
42. Wang SC, Chinn H. Experimental motion sickness in dogs: functional importance of chemoreceptive trigger zone. Am J Physiol 1954; 111-116
43. Nicholson AN, Pascoe PA, Spencer MB, Benson AJ. Jet lag and motion sickness. Br Med Bull 1993; 49: 285-304
44. Griffin MJ, Newman MM. Visual field effects on motion sickness in cars. Aviat Space Environ Med 2004; 75: 739-748
45. Golding JF, Prosyanikova O, Flynn M, Gresty MA. The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness. Auton Neurosci 2011; 160: 53-58
46. Yen Pik Sang FD, Billar JP, Golding JF, Gresty MA. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med 2003; 10: 108-111
47. Ming JL, Kuo BI, Lin JG, Lin LC. The efficacy of acupressure to prevent nausea and vomiting in post-operative patients. J Adv Nurs 2002; 39: 343-351
48. Alkaissi A, Ledin T, Odkvist LM, Kalman S. P6 acupressure increases tolerance to nauseogenic motion stimulation in women at high risk for PONV. Can J Anaesth 2005; 52: 703-709
49. Frey UH, Funk M, Lohlein C, Peters J. Effect of P6 acustimulation on post-operative nausea and vomiting in patients undergoing a laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2009; 53: 1341-1347
50. Frey UH, Scharmann P, Lohlein C, Peters J. P6 acustimulation effectively decreases postoperative nausea and vomiting in high-risk patients. Br J Anaesth 2009; 102: 620-625
51. Barsoum G, Perry EP, Fraser IA. Postoperative nausea is relieved by acupressure. J R Soc Med 1990; 83: 86-89
52. Bertolucci LE, DiDario B. Efficacy of a portable acustimulation device in controlling seasickness. Aviat Space Environ Med 1995; 66: 1155-1158
53. Bruce DG, Golding JF, Hockenhull N, Pethybridge RJ. Acupressure and motion sickness. Aviat Space Environ Med 1990; 61: 361-365
54. O'Brien B, Relyea MJ, Taerum T. Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. Am J Obstet Gynecol 1996; 174: 708-715
55. Dundee JW, Sourial FB, Ghaly RG, Bell PF. P6 acupressure reduces morning sickness. J R Soc Med 1988; 81: 456-457
56. Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66: 631-634
57. Stern RM, Jokerst MD, Muth ER, Hollis C. Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. Altern Ther Health Med 2001; 7: 91-94
58. Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004; 75: 227-234
59. Bertalanffy P, Hoerauf K, Fleischhackl R, Strasser H, Wicke F, Greher M, Gustorff B, Kober A. Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population. Anesth Analg 2004; 98: 220-223
60. Groen J. Adaptation. Pract Otorhinolaryngol 1957; 19: 524
61. Ruckenstein MJ, Harrison RV. Motion sickness. Helping patients tolerate the ups and downs. Postgrad Med 1991; 89: 139-144
62. Helling K, Westhofen M. Experimental studies of motion sickness on board of a research ship. HNO 1994; 42: 214-219
63. Held R. Exposure history as a factor in maintaining stability of perception and co-ordination. J Nerv Ment Dis 1961; 132: 26-32
64. Cha YH. Mal de debarquement. Semin Neurol 2009; 29: 520-527
65. De Florio PT, Silbergleit R. Mal de debarquement presenting in the emergency department. J Emerg Med 2006; 31: 377-379
66. Cha YH, Brodsky J, Ishiyama G, Sabatti C, Baloh RW. Clinical features and associated syndromes of mal de debarquement. J Neurol 2008; 255: 1038-1044
67. Moeller L, Lempert T. Mal de debarquement: pseudo-hallucinations from vestibular memory? J Neurol 2007; 254: 813-815
68. Takeda N, Morita M, Horii A, Nishiike S, Kitahara T, Uno A. Neural mechanisms of motion sickness. J Med Invest 2001; 48: 44-59
69. Wood CD, Graybiel A A theory of motion sickness based on pharmacological reactions. Clin Pharmacol Ther 1970; 11: 621-629
70. Gordon CR, Gonen A, Nachum Z, Doweck I, Spitzer O, Shupak A. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001; 15: 167-172
71. Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ 2011; 343:d7430
72. Schmal F, Stoll W. Medikamentose Schwindeltherapie. Laryngorhinootologie 2003; 82: 44-61
73. Matsuoka I, Ito J, Takahashi H, Sasa M, Takaori S. Experimental vestibular pharmacology: a minireview with special reference to neuroactive substances and antivertigo drugs. Acta Otolaryngol Suppl 1984; 419: 62-70
74. Becker G, Goossens H, Seemann K, Souchon F, Weitz T. Prevention of motion sickness with a transdermal therapeutic system containing scopolamine A randomized, comparative double-blind study in the German Federal Navy (in German). Dtsch Med Wochenschr 1984; 109: 1881-1885
75. Murray JB. Psychophysiological aspects of motion sickness. Percept Mot Skills 1997; 85: 1163-1167
76. Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I, Lavon H, Eynan M, Dachir S, Levy A. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001; 296: 121-123
77. Klocker N, Hanschke W, Toussaint S, Verse T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 2001; 13: 227-232
78. Simmons RG, Phillips JB, Lojewski RA, Wang Z, Boyd JL, Putcha L. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med 2010; 81: 405-412
79. Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011; 6:CD002851
80. Gil A, Nachum Z, Tal D, Shupak A A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol 2012; 35: 37-39
81. Gray L, Carliner P. The prevention and treatment of motion sickness. Science 1949; 109: 359
82. Wood CD, Kennedy RE, Graybiel A, Trumbull R, Wherry RJ. Clinical effectiveness of anti-motion-sickness drugs. Computer review of the literature. JAMA 1966; 198: 1155-1158
83. Valoti M, Frosini M, Dragoni S, Fusi F, Sgaragli G. Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. Methods Find Exp Clin Pharmacol 2003; 25: 377-381
84. Buckey JC, Alvarenga D, Cole B, Rigas JR. Chlorpheniramine for motion sickness. J Vestib Res 2004; 14: 53-61
85. Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007; 17: 301-311
86. Weinstein SE, Stern RM. Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997; 68: 890-894
87. Cheung BS, Heskin R, Hofer KD. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003; 37: 173-177
88. Stoot J. Mechanism and treatment of motion sickness; in Davis C, Lake Bakaar G, Grahame-Smith D (eds): Nausea and vomiting: mechanisms and treatment. Berlin, Springer, 1986
89. Ramanathan R, Geary RS, Bourne DW, Putcha L. Bioavailability of intranasal promethazine dosage forms in dogs. Pharmacol Res 1998; 38: 35-39
90. Cowings PS, Toscano WB, De Roshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000; 71: 1013-1022
91. Huang M, Gao JY, Zhai ZG, Liang QL, Wang YM, Bai YQ, Luo GA. An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. J Pharm Biomed Anal 2012; 62: 119-128
92. Kohl RL. Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. Aviat Space Environ Med 1987; 58: 125-131
93. Oman CM, Lichtenberg BK, Money KE, Mc-Coy RK. MIT/Canadian vestibular experiments on the Spacelab-1 mission. 4. Space motion sickness: symptoms, stimuli, and predictability. Exp Brain Res 1986; 64: 316-334
94. Rubio S, Weichenthal L, Andrews J. Motion sickness: comparison of metoclopramide and diphenhydramine to placebo. Prehosp Disaster Med 2011; 26: 305-309
95. Hershkovitz D, Asna N, Shupak A, Kaminski G, Bar R, Tal D. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 2009; 80: 643-646
96. Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007; 78: 686-692
97. Levine ME, Chillas JC, Stern RM, Knox GW. The effects of serotonin (5-HT 3 ) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. Aviat Space Environ Med 2000; 71: 1111-1114
98. Marcus DA, Furman JM, Balaban CD. Motion sickness in migraine sufferers. Expert Opin Pharmacother 2005; 6: 2691-2697
99. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 2005; 65: 620-622
100. Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a doubleblind, placebo-controlled pilot study. Med Sci Monit 2006; 12:I1-I7
101. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain 2011; 12: 81-88
102. Wang JJ, Dutia MB. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Exp Brain Res 1995; 105: 18-24
103. Gordon CR, Doweck I, Nachum Z, Gonen A, Spitzer O, Shupak A. Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea. J Vestib Res 2003; 13: 103-111
104. Matsnev EI, Sigaleva EE. Efficacy of histaminergic drugs in experimental motion sickness. J Vestib Res 2007; 17: 313-321
105. Albert EG. Phenytoin for the prevention of motion sickness. Med J Aust 2003; 178: 575-576
106. Otto B, Riepl RL, Otto C, Klose J, Enck P, Klosterhalfen S. Opiate receptor agonists - A new pharmacological approach to prevent motion sickness? Br J Clin Pharmacol 2006; 61: 27-30
107. Cohen B, Dai M, Yakushin SB, Raphan T. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res 2008; 171: 543-553
108. Conder GA, Sedlacek HS, Boucher JF, Clemence RG. Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. J Vet Pharmacol Ther 2008; 31: 528-532
109. Hickman MA, Cox SR, Mahabir S, Miskell C, Lin J, Bunger A, McCall RB. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008; 31: 220-229
110. Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986; 57: 45-48
111. Doweck I, Gordon CR, Spitzer O, Melamed Y, Shupak A. Effect of cinnarizine in the prevention of seasickness. Aviat Space Environ Med 1994; 65: 606-609
112. Shupak A, Doweck I, Gordon CR, Spitzer O. Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study. Clin Pharmacol Ther 1994; 55: 670-680
113. Jia L, Wang WY, Zhou LM, Mo FF, Li M. Antimotion sickness effects of ginsenosides combined with dexamethasone in rats (in Chinese). Zhong Xi Yi Jie He Xue Bao 2010; 8: 358-362
114. Lucertini M, Mirante N, Casagrande M, Trivelloni P, Lugli V. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007; 91: 180-190
115. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness A controlled trial on the open sea. Acta Otolaryngol 1988; 105: 45-49
116. Holtmann S, Clarke AH, Scherer H, Hohn M. The anti-motion sickness mechanism of ginger A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989; 108: 168-174
117. Mowrey DB, Clayson DE. Motion sickness, ginger, and psychophysics. Lancet 1982;i:655-657
118. Lien HC, Sun WM, Chen YH, Kim H, Hasler W, Owyang C. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003; 284:G481-G489
119. Chrubasik S, Pittler MH, Roufogalis BD. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 2005; 12: 684-701
120. Nicholson AN, Stone BM, Turner C, Mills SL. Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med 2002; 73: 570-574
121. Paul MA, MacLellan M, Gray G. Motionsickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005; 76: 560-565
122. Seibel K, Schaffler K, Reitmeir P, Golly I A randomised, placebo-controlled study comparing two formulations of dimenhydrinate with respect to efficacy in motion sickness and sedation. Arzneimittelforschung 2002; 52: 529-536